Short communication
TsAg5, a Taenia solium cysticercus protein with a marginal trypsin-like activity in the diagnosis of human neurocysticercosis

https://doi.org/10.1016/j.molbiopara.2011.08.003Get rights and content

Abstract

Neurocysticercosis is an endemic parasitic disease caused by Taenia solium larva. Although the mechanism of infection is not completely understood, it is likely driven by proteolytic activity that degrades the intestinal wall to facilitate oncosphere penetration and further infection.

We analyzed the publicly available T. solium EST/DNA library and identified two contigs comprising a full-length cDNA fragment very similar to Echinococcus granulosus Ag5 protein. The T. solium cDNA sequence included a proteolytic trypsin-like-domain in the C-terminal region, and a thrombospondin type-1 adherence-domain in the N-terminal region. Both the trypsin-like and adherence domains were expressed independently as recombinant proteins in bacterial systems. TsAg5 showed marginal trypsin-like activity and high sequence similarity to Ag5. The purified antigens were tested in a Western immunoblot assay to diagnose human neurocysticercosis. The sensitivity of the trypsin-like-domain was 96.36% in patients infected with extraparenchymal cysts, 75.44% in patients infected with multiple cysts, and 39.62% in patients with a single cyst. Specificity was 76.70%. The thrombospondin type-1 adherence-domain was not specific for neurocysticercosis.

Graphical abstract

A Taenia solium recombinant antigen homologous to Echinococcus granulosus Ag5 with a trypsin-like domain and an adherence-domain is characterized and tested as an immunodiagnostics antigen.

  1. Download : Download high-res image (116KB)
  2. Download : Download full-size image

Highlights

► TsAg5 was found in the excretory/secretory antigens of the cysticercus and in the oncosphere. ► The trypsin-like domain of TsAg5 showed a marginal proteolytic activity. ► The trypsin-like domain showed to be an important antigen for immunodiagnostics of multiple cyst and extra-parenchymal NCC. ► The adherence domain of TsAg5 was not specific.

Section snippets

Financial support

This work was partially funded by research grants numbers CRP/PER08-02 from the ICGEB, P01 AI51976 TMRC, D43 TW001140 (Fogarty Training), and D43 TW007120 from the National Institutes of Health, USA. The sponsors had no role in the design or writing of this manuscript.

References (23)

  • A.S. Juncker et al.

    Prediction of lipoprotein signal peptides in Gram-negative bacteria

    Protein Sci

    (2003)
  • Cited by (10)

    • Serine proteases in schistosomes and other trematodes

      2018, International Journal for Parasitology
      Citation Excerpt :

      The SmSP2 orthologs from S. japonicum and S. haematobium (in the genome databases annotated as mastins) were identified as antigens targeted by IgG1 in praziquantel-treated humans with acquired full resistance (Pearson et al., 2015). Remarkably, SmSP2 orthologs present in the larval stage (cysticercus) of the cestodes (Lorenzo et al., 2003; Rueda et al., 2011) were identified as major components of cyst fluid, termed Antigen 5 excretory proteins (Ag5). These Ag5 proteins are now used as a serodiagnostic test against cysticercosis (Li et al., 2012; Rueda et al., 2011).

    • Cysticercosis/taeniasis endemicity in Southeast Asia: Current status and control measures

      2017, Acta Tropica
      Citation Excerpt :

      In pig keeping practices, even in rural areas, it is recognized that vaccinations of farm animals can prevent pathogenic infections and therefore improve the commercial value of the pork. Recently, a vaccine for preventing porcine cysticercosis (TSOL18) has been proven to be highly effective against naturally acquired infection with T. solium in pigs in several field trials (Assana et al., 2010; Garcia et al., 2007; Gauci et al., 2012; Gonzalez et al., 2011, 2012; Jayashi et al., 2012a,b; Martinez-Ocana et al., 2011; Pina et al., 2011; Rueda et al., 2011; Verle et al., 2003; Zimic et al., 2011). It will be a great tool for combating cysticercosis (Lightowlers, 2013; WHO, 2011a).

    • Trends in the diagnosis of human neurocysticercosis: Issues and challenges

      2021, Neurocysticercosis: From Diagnosis to Treatment
    • Treatment of neurocysticercosis: Current and future options

      2021, Neurocysticercosis: From Diagnosis to Treatment
    View all citing articles on Scopus
    1

    For the Cysticercosis Working Group in Peru.

    View full text